EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Efficacy and safety of Atezolizumab plus Bevacizumab and Lenvatinib as first-line systemic therapies for hepatocellular carcinoma: A real-world study

Sangdao Boonkaya iD, Chidkamon Pattarawongpaiboon iD, Panarat Thaimai, Prooksa Ananchuensook, Supachaya Sriphoosanaphan, Suebpong Tanasanvimon, Nattaya Teeyapun, Nussara Pakvisal, Nipaporn Siripon, Sombat Treeprasertsuk, Piyawat Komolmit, Kessarin Thanapirom iD

PLOS One · 2025

DOI: 10.1371/journal.pone.0337351 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS One, 2025. Verfasst von Sangdao Boonkaya und 11 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology, Department of Medicine, Faculty of Medicine, Chulalongkorn University and King Chulalongkorn Memorial Hospital, Thai Re…. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Quinolines, Phenylurea Compounds. Die Arbeit nennt 13 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ratchadapiseksompotch Endowment Fund of the Center of Excellence in Hepatic Fibrosis and Cirrhosis Research Unit.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Atezolizumab plus bevacizumab (ATEZO/BEV) and Lenvatinib (LEN) have demonstrated efficacy as first-line systemic therapies for unresectable hepatocellular carcinoma (HCC). This study aimed to compare the efficacy, safety, and outcomes of these two treatments. Data were retrospectively collected from 163 patients with unresectable HCC receiving first-line Lenvatinib (LEN) (n = 85) or ATEZO/BEV (n = 78) between 2020 and 2023 at Chulalongkorn University Hospital in Bangkok, Thailand. The primary outcome was overall survival (OS) following treatment. Propensity score matching (PSM) was used for analysis. The median patient age was 60.6 (SD 11.8) years; 82.2% were male. Most had hepatitis B/C (66.9%), BCLC stage C (73%), and Child-Pugh class A cirrhosis (63.8%). After PSM analysis, overall survival (OS) was significantly longer in the ATEZO/BEV group (12.7 vs. 7.5 months; p = 0.016, HR = 0.618, 95% CI: 0.417–0.916). However, there was no significant difference in progression-free survival (PFS) between ATEZO/BEV and LEN groups (10.8 vs. 7.8 months; p = 0.26, HR = 0.73, 95% CI: 0.431–1.255). Assessed by mRECIST, neither objective response rate (ORR: 23.7% vs. 19.7%, p = 0.555) nor disease control rate (DCR: 36.8% vs. 38.2%, p = 0.867) differed significantly. Multivariate analysis revealed alpha-fetoprotein ≥500 ng/mL (HR = 1.881, 95% CI: 1.028–3.443, p = 0.04), tumor size (HR = 1.833, 95% CI: 1.010–3.327, p = 0.046) and ATEZO/BEV therapy (HR = 0.604, 95%CI: 0.373–0.977, p = 0.04) were independently associated with OS. Adverse event rates were comparable (ATEZO/BEV 43.7% vs. LEN 56.3%; p = 0.08). In conclusion, the study demonstrates that ATEZO/BEV significantly improves OS compared to LEN in patients with unresectable HCC, despite similar PFS, ORR, and DCR. Both treatments have comparable safety profiles.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularLiver NeoplasmsQuinolinesPhenylurea CompoundsAntibodies, Monoclonal, HumanizedBevacizumabAntineoplastic Combined Chemotherapy ProtocolsHumansMaleFemaleMiddle AgedRetrospective StudiesAgedTreatment Outcome

Substanzen

lenvatinibQuinolinesPhenylurea CompoundsAntibodies, Monoclonal, HumanizedBevacizumabatezolizumab

Autor:innen und Institutionen

  • Division of Gastroenterology, Department of Medicine, Faculty of Medicine, Chulalongkorn University and King Chulalongkorn Memorial Hospital, Thai Red Cross Society, Bangkok, Thailand.
  • Department of Internal Medicine, Queen Savang Vadhana Memorial Hospital, Chonburi, Thailand.
  • Center of Excellence in Hepatic Fibrosis and Cirrhosis, Chulalongkorn University, Bangkok, Thailand.
  • Excellence Center in Liver Diseases, King Chulalongkorn Memorial Hospital, Thai Red Cross Society, Bangkok, Thailand.
  • Division of Oncology, Department of Medicine, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.

ORCID-Profile: Sangdao Boonkaya, Chidkamon Pattarawongpaiboon, Kessarin Thanapirom

Förderung

  • Ratchadapiseksompotch Endowment Fund of the Center of Excellence in Hepatic Fibrosis and Cirrhosis Research Unit

Zitieren

APA

Boonkaya, S., Pattarawongpaiboon, C., Thaimai, P., Ananchuensook, P., Sriphoosanaphan, S., Tanasanvimon, S., Teeyapun, N., Pakvisal, N., Siripon, N., Treeprasertsuk, S., Komolmit, P., & Thanapirom, K. (2025). Efficacy and safety of Atezolizumab plus Bevacizumab and Lenvatinib as first-line systemic therapies for hepatocellular carcinoma: A real-world study. PLOS One. https://doi.org/10.1371/journal.pone.0337351

Vancouver

Boonkaya S, Pattarawongpaiboon C, Thaimai P, Ananchuensook P, Sriphoosanaphan S, Tanasanvimon S, et al. Efficacy and safety of Atezolizumab plus Bevacizumab and Lenvatinib as first-line systemic therapies for hepatocellular carcinoma: A real-world study. PLOS One. 2025. doi:10.1371/journal.pone.0337351

BibTeX
@article{Boonkaya2025,
  author = {Boonkaya, Sangdao and Pattarawongpaiboon, Chidkamon and Thaimai, Panarat and Ananchuensook, Prooksa and Sriphoosanaphan, Supachaya and Tanasanvimon, Suebpong and Teeyapun, Nattaya and Pakvisal, Nussara and Siripon, Nipaporn and Treeprasertsuk, Sombat and Komolmit, Piyawat and Thanapirom, Kessarin},
  title = {Efficacy and safety of Atezolizumab plus Bevacizumab and Lenvatinib as first-line systemic therapies for hepatocellular carcinoma: A real-world study},
  journal = {PLOS One},
  year = {2025},
  doi = {10.1371/journal.pone.0337351}
}
Kostenlos starten →